Astellas Pharma
10
17M
10
0.53
4
4
- Areas of investment
Summary
Astellas Pharma is the famous Corporate Investor, which was founded in 2005. The main department of described Corporate Investor is located in the Tokyo. The fund was located in Asia if to be more exact in Japan.
The fund has specific favorite in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Life Science. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight FibroGen, CoMentis, Catalia Health.
The fund was created by Erik Karrer.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Astellas Pharma, startups are often financed by Khosla Ventures, Wellington Partners, Silicon Valley Growth Syndicate. The meaningful sponsors for the fund in investment in the same round are The House Fund, Shibuya Kogyo, Shanda Group. In the next rounds fund is usually obtained by Tony Ling, SMBC Venture Capital, SBI Investment.
The top amount of exits for fund were in 2017. Considering the real fund results, this Corporate Investor is 23 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Astellas Pharma works on 0 percentage points less the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 4
- Exits
- 4
- Rounds per year
- 0.53
- Investments by industry
- Biotechnology (6)
- Health Care (5)
- Medical (2)
- Life Science (2)
- Therapeutics (2) Show 8 more
- Investments by region
-
- United States (9)
- Japan (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 139M
- Group Appearance index
- 0.60
- Avg. company exit year
- 5
- Avg. multiplicator
- 2.32
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Mitobridge | 04 Oct 2013 | Biotechnology, Life Science, Therapeutics | Early Stage Venture | 5M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.